ArticleSensors (Basel, Switzerland)2024
Advancing Breast Cancer Diagnosis through Breast Mass Images, Machine Learning, and Regression Models.
Article in Sensors (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 17 citations in OpenAlex.
- A Multi-Criterion Selection of Hybrid Features in Mammographic Imaging for Early Computer-Assisted Sensing and Detection of Breast Cancer.Sensors (Basel, Switzerland) · 2026Article
- Serum Protein Signatures for Breast Cancer Detection in Treatment-Naïve African American Women Using Integrated Proteomics and Pattern Analysis.Sensors (Basel, Switzerland) · 2026Article
- Investigating the Key Trends in Applying Artificial Intelligence to Health Technologies: A Scoping Review.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer results from a disruption of certain cells in breast tissue that undergo uncontrolled growth and cell division. These cells most often accumulate and form a lump called a tumor, which may be benign (non-cancerous) or malignant (cancerous). Malignant tumors can spread quickly throughout the body, forming tumors in other areas, which is called metastasis. Standard screening techniques are insufficient in the case of metastasis; therefore, new and advanced techniques based on artificial intelligence (AI), machine learning, and regression models have been introduced, the primary aim of which is to automatically diagnose breast cancer through the use of advanced techniques, classifiers, and real images. Real fine-needle aspiration (FNA) images were collected from Wisconsin, and four classifiers were used, including three machine learning models and one regression model: the support vector machine (SVM), naive Bayes (NB), k-nearest neighbors (k-NN), and decision tree (DT)-C4.5. According to the accuracy, sensitivity, and specificity results, the SVM algorithm had the best performance; it was the most powerful computational classifier with a 97.13% accuracy and 97.5% specificity. It also had around a 96% sensitivity for the diagnosis of breast cancer, unlike the models used for comparison, thereby providing an exact diagnosis on the one hand and a clear classification between benign and malignant tumors on the other hand. As a future research prospect, more algorithms and combinations of features can be considered for the precise, rapid, and effective classification and diagnosis of breast cancer images for imperative decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.